99% purity retatrutide 5mg 10mg 100mg powder for weight loss

Pls input...

I. Introduction

Retatrutide (development code: LY3437943) is an investigational synthetic peptide developed by Eli Lilly and Company. It represents a novel class of triple-receptor agonist therapies designed to target multiple metabolic hormone receptors simultaneously.

Development Status: As of 2026, retatrutide remains in Phase 3 clinical trials under the TRIUMPH program. It has not received regulatory approval as a commercial medicine in any jurisdiction. It is currently distributed as a research-use-only (RUO) compound for laboratory and preclinical investigation.

II. Application Areas

1. Obesity and Weight Management

Retatrutide has demonstrated the most substantial weight-loss efficacy among all incretin-based therapies investigated to date. In the Phase 3 TRIUMPH-1 trial, the 12 mg dose achieved a mean body weight reduction of 28.3% at 80 weeks, with extension data approaching 30%+ reduction. This surpasses the efficacy of currently approved dual-agonist and single-agonist therapies.

2. Type 2 Diabetes Mellitus (T2DM)

In patients with type 2 diabetes and inadequate glycemic control on diet and exercise, retatrutide has shown significant improvements in HbA1c levels and fasting plasma glucose. Its triple-agonist mechanism provides both insulinotropic and glucoregulatory effects that address multiple pathophysiological defects in T2DM.

3. Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Retatrutide is being investigated for the treatment of MASH (formerly NASH). Its combined effects on weight reduction, insulin sensitivity, and hepatic lipid metabolism suggest potential for resolving steatohepatitis and reducing liver fibrosis progression.

4. Cardiovascular and Metabolic Risk Reduction

Through its effects on body weight, glycemic control, lipid profiles, and inflammatory markers, retatrutide may reduce overall cardiometabolic risk. Improvements in triglycerides, LDL cholesterol, and liver enzymes have been observed in clinical studies.

5. Research and Preclinical Applications

As a research compound, retatrutide is used in:

• Receptor pharmacology studies (GIPR, GLP-1R, GCGR binding and signaling)
• Metabolic pathway research
• Obesity and diabetes animal models
• Peptide drug development and structure-activity relationship (SAR) studies
• Comparative efficacy studies against semaglutide, tirzepatide, and other incretin mimetics

III. Mechanism of Action

Retatrutide exerts its therapeutic effects through simultaneous agonism of three distinct metabolic hormone receptors, a mechanism that distinguishes it from single-agonist (e.g., semaglutide) and dual-agonist (e.g., tirzepatide) therapies.

1. GLP-1 Receptor (GLP-1R) Agonism

• Glucose-dependent insulin secretion: Stimulates pancreatic β-cells to release insulin only when blood glucose levels are elevated, reducing hypoglycemia risk
• Appetite suppression: Acts on hypothalamic centers to reduce hunger and increase satiety, leading to reduced caloric intake
• Gastric emptying delay: Slows gastrointestinal transit, prolonging postprandial fullness
• β-cell protection: May preserve pancreatic β-cell function and reduce apoptosis

2. GIP Receptor (GIPR) Agonism

• Enhanced insulinotropic effect: Complements GLP-1R signaling to amplify glucose-dependent insulin release
• Carbohydrate and lipid partitioning: Optimizes nutrient distribution, promoting fat oxidation and improving metabolic flexibility
• Adipose tissue modulation: Regulates adipocyte function and lipid storage dynamics
• Central nervous system effects: May contribute to appetite regulation and energy balance when combined with GLP-1R activation

3. Glucagon Receptor (GCGR) Agonism

• Increased energy expenditure: Stimulates hepatic glucose production and thermogenesis, raising basal metabolic rate
• Enhanced fat oxidation: Promotes lipolysis and fatty acid oxidation in adipose tissue and liver
• Hepatic lipid reduction: Reduces hepatic steatosis by mobilizing triglycerides from the liver
• Synergistic weight loss: The catabolic effects of glucagon receptor activation complement the appetite-suppressing effects of GLP-1/GIP agonism, producing greater weight reduction than dual or single agonists alone

4. Pharmacokinetic Design

The C20 fatty acid diacid side chain attached to the peptide backbone enables:

• Albumin binding: Reversible binding to circulating albumin extends plasma residence time
• Slow absorption: Delayed subcutaneous absorption supports once-weekly dosing
• Renal protection: Reduces glomerular filtration and urinary excretion
• Protease resistance: Structural modifications (including Aib and α-methyl-Leu substitutions) enhance stability against peptidase degradation

5. Integrated Metabolic Outcome

The convergence of these three receptor pathways produces a synergistic metabolic profile:

• Reduced energy intake (GLP-1 + GIP central appetite effects)
• Increased energy expenditure (glucagon-mediated thermogenesis)
• Improved glycemic control (GLP-1 + GIP insulinotropic effects)
• Enhanced lipid mobilization (glucagon lipolysis + GIP partitioning)
• Hepatic metabolic improvement (reduced steatosis, improved insulin sensitivity)